COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans.

Autor:	Laniece Delaunay C; Epidemiology Department, Epiconcept, Paris, France., Mazagatos C; National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain.; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain., Martínez-Baz I; Instituto de Salud Pública de Navarra-IdiSNA, Pamplona, Spain., Túri G; National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary., Goerlitz L; Department for Infectious Disease Epidemiology, Unit 36 Respiratory Infections, Robert Koch Institute, Berlin, Germany., Domegan L; Health Service Executive-Health Protection Surveillance Centre, Dublin, Ireland., Meijer A; Centre for Infectious Diseases Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands., Rodrigues AP; Epidemiology Department, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal., Sève N; Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France., Ilic M; Division for Epidemiology of Communicable Diseases, Croatian Institute of Public Health, Zagreb, Croatia., Latorre-Margalef N; Department of Microbiology, The Public Health Agency of Sweden, Stockholm, Sweden., Lazar M; National Influenza Centre, 'Cantacuzino' National Military-Medical Institute for Research and Development, Bucharest, Romania., Maurel M; Epidemiology Department, Epiconcept, Paris, France., Melo A; Reference Laboratory for Influenza and Other Respiratory Virus, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal., Andreu Ivorra B; Servicio de Epidemiología, Sección de Vigilancia Epidemiológica, Consejería de Salud de Murcia, Murcia, Spain., Casado I; Instituto de Salud Pública de Navarra-IdiSNA, Pamplona, Spain., Horváth JK; National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary., Buda S; Department for Infectious Disease Epidemiology, Unit 36 Respiratory Infections, Robert Koch Institute, Berlin, Germany., Bennett C; National Virus Reference Laboratory, University College Dublin, Dublin, Ireland., de Lange M; Centre for Infectious Diseases Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands., Guiomar R; Reference Laboratory for Influenza and Other Respiratory Virus, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal., Enouf V; Institut Pasteur, Centre National de Référence Virus des Infections Respiratoires (CNR VIR), Paris, France., Mlinaric I; Division for Epidemiology of Communicable Diseases, Croatian Institute of Public Health, Zagreb, Croatia., Samuelsson Hagey T; Department of Microbiology, The Public Health Agency of Sweden, Stockholm, Sweden., Dinu S; National Influenza Centre, 'Cantacuzino' National Military-Medical Institute for Research and Development, Bucharest, Romania., Rumayor M; Área de Enfermedades Transmisibles, Subdirección General de Vigilancia en Salud Pública, Madrid, Spain., Castilla J; Instituto de Salud Pública de Navarra-IdiSNA, Pamplona, Spain., Oroszi B; National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary., Dürrwald R; Department of Infectious Diseases, Unit 17 Influenza and Other Respiratory Viruses, Robert Koch Institute, Berlin, Germany., O'Donnell J; Health Service Executive-Health Protection Surveillance Centre, Dublin, Ireland., Hooiveld M; Nivel (Netherlands Institute for Health Services Research), Utrecht, the Netherlands., Gomez V; Epidemiology Department, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal., Falchi A; Laboratoire de Virologie, UR7310 Campus Grimaldi, Université de Corse, Corte, France., Kurecic Filipovic S; Division for Epidemiology of Communicable Diseases, Croatian Institute of Public Health, Zagreb, Croatia., Dillner L; Department of Microbiology, The Public Health Agency of Sweden, Stockholm, Sweden., Popescu R; National Center for Communicable Diseases Surveillance and Control, National Institute of Public Health, Bucharest, Romania., Bacci S; European Centre for Disease Prevention and Control, Stockholm, Sweden., Kaczmarek M; European Centre for Disease Prevention and Control, Stockholm, Sweden., Kissling E; Epidemiology Department, Epiconcept, Paris, France.
Jazyk:	angličtina
Zdroj:	JAMA network open [JAMA Netw Open] 2024 Jul 01; Vol. 7 (7), pp. e2419258. Date of Electronic Publication: 2024 Jul 01.
DOI:	10.1001/jamanetworkopen.2024.19258
Abstrakt:	Importance: In the context of emerging SARS-CoV-2 variants or lineages and new vaccines, it is key to accurately monitor COVID-19 vaccine effectiveness (CVE) to inform vaccination campaigns. Objective: To estimate the effectiveness of COVID-19 vaccines administered in autumn and winter 2022 to 2023 against symptomatic SARS-CoV-2 infection (with all circulating viruses and XBB lineage in particular) among people aged 60 years or older in Europe, and to compare different CVE approaches across the exposed and reference groups used. Design, Setting, and Participants: This case-control study obtained data from VEBIS (Vaccine Effectiveness, Burden and Impact Studies), a multicenter study that collects COVID-19 and influenza data from 11 European sites: Croatia; France; Germany; Hungary; Ireland; Portugal; the Netherlands; Romania; Spain, national; Spain, Navarre region; and Sweden. Participants were primary care patients aged 60 years or older with acute respiratory infection symptoms who were recruited at the 11 sites after the start of the COVID-19 vaccination campaign from September 2022 to August 2023. Cases and controls were defined as patients with positive and negative, respectively, reverse transcription-polymerase chain reaction (RT-PCR) test results. Exposures: The exposure was COVID-19 vaccination. The exposure group consisted of patients who received a COVID-19 vaccine during the autumn and winter 2022 to 2023 vaccination campaign and 14 days or more before symptom onset. Reference group included patients who were not vaccinated during or in the 6 months before the 2022 to 2023 campaign (seasonal CVE), those who were never vaccinated (absolute CVE), and those who were vaccinated with at least the primary series 6 months or more before the campaign (relative CVE). For relative CVE of second boosters, patients receiving their second booster during the campaign were compared with those receiving 1 booster 6 months or more before the campaign. Main Outcomes and Measures: The outcome was RT-PCR-confirmed, medically attended, symptomatic SARS-CoV-2 infection. Four CVE estimates were generated: seasonal, absolute, relative, and relative of second boosters. CVE was estimated using logistic regression, adjusting for study site, symptom onset date, age, chronic condition, and sex. Results: A total of 9308 primary care patients were included, with 1687 cases (1035 females; median [IQR] age, 71 [65-79] years) and 7621 controls (4619 females [61%]; median [IQR] age, 71 [65-78] years). Within 14 to 89 days after vaccination, seasonal CVE was 29% (95% CI, 14%-42%), absolute CVE was 39% (95% CI, 6%-60%), relative CVE was 31% (95% CI, 15% to 44%), and relative CVE of second boosters was 34% (95% CI, 18%-47%) against all SARS-CoV-2 variants. In the same interval, seasonal CVE was 44% (95% CI, -10% to 75%), absolute CVE was 52% (95% CI, -23% to 82%), relative CVE was 47% (95% CI, -8% to 77%), and relative CVE of second boosters was 46% (95% CI, -13% to 77%) during a period of high XBB circulation. Estimates decreased with time since vaccination, with no protection from 180 days after vaccination. Conclusions and Relevance: In this case-control study among older Europeans, all CVE approaches suggested that COVID-19 vaccines administered in autumn and winter 2022 to 2023 offered at least 3 months of protection against symptomatic, medically attended, laboratory-confirmed SARS-CoV-2 infection. The effectiveness of new COVID-19 vaccines against emerging SARS-CoV-2 variants should be continually monitored using CVE seasonal approaches.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu